461 related articles for article (PubMed ID: 17662999)
1. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
2. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
4. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
5. Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin.
Lee YS; Marcu MG; Neckers L
Chem Biol; 2004 Jul; 11(7):991-8. PubMed ID: 15271357
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
8. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
9. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
Zhang MQ; Gaisser S; Nur-E-Alam M; Sheehan LS; Vousden WA; Gaitatzis N; Peck G; Coates NJ; Moss SJ; Radzom M; Foster TA; Sheridan RM; Gregory MA; Roe SM; Prodromou C; Pearl L; Boyd SM; Wilkinson B; Martin CJ
J Med Chem; 2008 Sep; 51(18):5494-7. PubMed ID: 18800759
[TBL] [Abstract][Full Text] [Related]
10. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90.
Itoh H; Ogura M; Komatsuda A; Wakui H; Miura AB; Tashima Y
Biochem J; 1999 Nov; 343 Pt 3(Pt 3):697-703. PubMed ID: 10527951
[TBL] [Abstract][Full Text] [Related]
11. Geldanamycin inhibits tyrosine phosphorylation-dependent NF-kappaB activation.
Crèvecoeur J; Merville MP; Piette J; Gloire G
Biochem Pharmacol; 2008 Jun; 75(11):2183-91. PubMed ID: 18455150
[TBL] [Abstract][Full Text] [Related]
12. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
[TBL] [Abstract][Full Text] [Related]
13. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
14. Rational biosynthetic engineering for optimization of geldanamycin analogues.
Kim W; Lee D; Hong SS; Na Z; Shin JC; Roh SH; Wu CZ; Choi O; Lee K; Shen YM; Paik SG; Lee JJ; Hong YS
Chembiochem; 2009 May; 10(7):1243-51. PubMed ID: 19308924
[TBL] [Abstract][Full Text] [Related]
15. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
16. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
17. Cancer: the rules of attraction.
Neckers L; Lee YS
Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
[No Abstract] [Full Text] [Related]
18. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
19. Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90.
Millson SH; Chua CS; Roe SM; Polier S; Solovieva S; Pearl LH; Sim TS; Prodromou C; Piper PW
FASEB J; 2011 Nov; 25(11):3828-37. PubMed ID: 21778327
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 regulates development in Dictyostelium discoideum.
Sawarkar R; Roy N; Rao S; Raman S; Venketesh S; Suguna K; Tatu U
J Mol Biol; 2008 Oct; 383(1):24-35. PubMed ID: 18718841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
